191 related articles for article (PubMed ID: 18221871)
1. Pyrazinoindolone inhibitors of MAPKAP-K2.
Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z
Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR studies of indole-based MK2 inhibitors.
Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
[TBL] [Abstract][Full Text] [Related]
3. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
Wu JP; Wang J; Abeywardane A; Andersen D; Emmanuel M; Gautschi E; Goldberg DR; Kashem MA; Lukas S; Mao W; Martin L; Morwick T; Moss N; Pargellis C; Patel UR; Patnaude L; Peet GW; Skow D; Snow RJ; Ward Y; Werneburg B; White A
Bioorg Med Chem Lett; 2007 Aug; 17(16):4664-9. PubMed ID: 17576063
[TBL] [Abstract][Full Text] [Related]
4. Meroterpenoid MAPKAP (MK2) inhibitors isolated from the indonesian marine sponge Acanthodendrilla sp.
Williams DE; Telliez JB; Liu J; Tahir A; van Soest R; Andersen RJ
J Nat Prod; 2004 Dec; 67(12):2127-9. PubMed ID: 15620270
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.
Kosugi T; Mitchell DR; Fujino A; Imai M; Kambe M; Kobayashi S; Makino H; Matsueda Y; Oue Y; Komatsu K; Imaizumi K; Sakai Y; Sugiura S; Takenouchi O; Unoki G; Yamakoshi Y; Cunliffe V; Frearson J; Gordon R; Harris CJ; Kalloo-Hosein H; Le J; Patel G; Simpson DJ; Sherborne B; Thomas PS; Suzuki N; Takimoto-Kamimura M; Kataoka K
J Med Chem; 2012 Aug; 55(15):6700-15. PubMed ID: 22746295
[TBL] [Abstract][Full Text] [Related]
6. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
[TBL] [Abstract][Full Text] [Related]
7. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401
[TBL] [Abstract][Full Text] [Related]
8. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
[TBL] [Abstract][Full Text] [Related]
10. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a series of multi-isoform PI3 kinase inhibitors.
Perry B; Beevers R; Bennett G; Buckley G; Crabbe T; Gowers L; James L; Jenkins K; Lock C; Sabin V; Wright S
Bioorg Med Chem Lett; 2008 Oct; 18(19):5299-302. PubMed ID: 18774713
[TBL] [Abstract][Full Text] [Related]
13. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
16. Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy.
Velcicky J; Feifel R; Hawtin S; Heng R; Huppertz C; Koch G; Kroemer M; Moebitz H; Revesz L; Scheufler C; Schlapbach A
Bioorg Med Chem Lett; 2010 Feb; 20(3):1293-7. PubMed ID: 20060294
[TBL] [Abstract][Full Text] [Related]
17. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
[TBL] [Abstract][Full Text] [Related]
18. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
19. Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
Moree WJ; Goldman P; Demaggio AJ; Christenson E; Herendeen D; Eksterowicz J; Kesicki EA; McElligott DL; Beaton G
Bioorg Med Chem Lett; 2008 Sep; 18(18):5126-9. PubMed ID: 18713665
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
